Assembly Biosciences Inc (ASMB) Shares Bought by Lyon Street Capital LLC

Lyon Street Capital LLC raised its stake in shares of Assembly Biosciences Inc (NASDAQ:ASMB) by 9.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 149,443 shares of the biopharmaceutical company’s stock after purchasing an additional 13,243 shares during the quarter. Assembly Biosciences accounts for about 2.0% of Lyon Street Capital LLC’s holdings, making the stock its 22nd biggest holding. Lyon Street Capital LLC owned approximately 0.75% of Assembly Biosciences worth $5,219,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Assembly Biosciences by 21.2% in the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock worth $12,615,000 after acquiring an additional 107,065 shares during the last quarter. State Street Corp bought a new stake in shares of Assembly Biosciences in the 2nd quarter worth approximately $4,234,000. Northern Trust Corp lifted its holdings in shares of Assembly Biosciences by 221.2% in the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock worth $4,033,000 after acquiring an additional 134,513 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Assembly Biosciences by 6.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock worth $5,944,000 after acquiring an additional 11,412 shares during the last quarter. Finally, AXA bought a new stake in shares of Assembly Biosciences in the 2nd quarter worth approximately $2,477,000. Institutional investors and hedge funds own 62.09% of the company’s stock.

Assembly Biosciences Inc (NASDAQ:ASMB) opened at $44.12 on Wednesday. Assembly Biosciences Inc has a one year low of $11.07 and a one year high of $52.37.

In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total value of $29,550.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 3,000 shares of company stock worth $112,620. 19.60% of the stock is owned by insiders.

ASMB has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a report on Wednesday, November 15th. Jefferies Group initiated coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective for the company. Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. Finally, BidaskClub raised shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th.

WARNING: This story was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://stocknewstimes.com/2017/12/06/assembly-biosciences-inc-asmb-shares-bought-by-lyon-street-capital-llc.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply